Menu Search
Equities

Karyopharm Therapeutics Inc

25K:BER

Karyopharm Therapeutics Inc

Actions
  • Price (EUR)0.831
  • Today's Change-0.009 / -1.02%
  • Shares traded--
  • 1 Year change+19.60%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Karyopharm Therapeutics Inc had revenues fall -7.03% from 157.07m to 146.03m, though the company grew net income from a loss of 165.29m to a smaller loss of 143.10m.
Gross margin95.85%
Net profit margin-58.93%
Operating margin-54.75%
Return on assets-38.08%
Return on equity--
Return on investment-52.09%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Karyopharm Therapeutics Inc fell by 83.69m. However, Cash Flow from Investing totalled 7.94m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 92.72m for operations while cash generated from financing totalled 1.12m.
Cash flow per share-0.6839
Price/Cash flow per share--
Book value per share-1.27
Tangible book value per share-1.27
More ▼

Balance sheet in USDView more

Karyopharm Therapeutics Inc appears to have a weak balance sheet, highlighted by its negative owner's equity. Additionally, this company's debt load outweighs its assets while day-to-day operations are losing money. One plus is that there are enough liquid assets to satisfy current obligations, however, this situation is unsustainable over the long run. Karyopharm Therapeutics Inc has considerable financial risk.
Current ratio3.00
Quick ratio2.93
Total debt/total equity--
Total debt/total capital2.53
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.